MR-146A Phase 1/2, Single-Dose, Multicenter, Dose Escalation, Clinical Trial to Evaluate the Safety and Efficacy of MR-146: An Open-Label Part 1 in Participants With Stage 1 or 2 Neurotrophic Keratopathy and a Double-Masked Part 2 in Participants With Stage 2 Neurotrophic Keratopathy

Inclusion Criteria:

1. Be ≥18 years or greater of age at Visit 1.
2. Have a diagnosis of Stage 1 or Stage 2 in the study eye for Part 1 or Stage 2 NK in the study eye for Part 2.
3. Willing and able to participate in and attend to all study visits over the course of 12-14 months

Exclusion Criteria:

1. Have Stage 2 NK affecting both eyes, or Stage 3 NK in either eye.
2. Any active ocular infections or active ocular inflammation not related to NK in the affected eye.
3. Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study
4. Have monocular vision in the study eye or have BSCVA less than 20/100 in the fellow eye.
5. Any neurodegenerative disease (example: Parkinson's, Alzheimer's, Multiple Sclerosis, etc)
6. Uncontrolled glaucoma in either eye.
7. Any plan to use therapeutic contact lenses.
8. Anyone pregnant, nursing, or planning to become pregnant within 3 months of participating in the study.
9. History of incisional conjunctival surgery in the study eye.
10. History of any ocular surgery in the affected eye within the last 3 months
11. Botox use in the face or orbital area and/or lacrimal gland within the last 6 months.